SCIENTIFIC REPORTS

Published online: 23 October 2018

OPEN Author Correction: Acylatedacyl carrier protein stabilizes the Pseudomonas aeruginosa WaaP lipopolysaccharide heptose kinase

Naomi N. K. Kreamer¹, Rajiv Chopra², Ruth E. Caughlan¹, Doriano Fabbro³, Eric Fang¹, Patricia Gee², Ian Hunt², Min Li¹, Barbara C. Leon¹, Lionel Muller³, Brian Vash², Angela L. Woods¹, Travis Stams², Charles R. Dean¹ & Tsuyoshi Uehara¹

Correction to: Scientific Reports https://doi.org/10.1038/s41598-018-32379-1, published online 20 September 2018

This Article contains errors in the Results section under the subheading 'Role of acyl-ACP/WaaP interaction'.

"A similar level of WaaP-FLAG protein was produced regardless of the presence or absence of only detected in the supernatant after ultracentrifugation when acyl-ACP was present, as shown by anti-FLAG western blot (Fig. 4) and SYPRO Orange stained protein gel (Supplementary Fig. 4)".

should read:

"A similar level of WaaP-FLAG protein was produced regardless of the presence or absence of acyl-ACP or of non-acylated ACP proteins or fatty acid in the reaction mixture (Fig. 4). However, WaaP was only detected in the supernatant after ultracentrifugation when acyl-ACP was present, as shown by anti-FLAG western blot (Fig. 4) and SYPRO Orange stained protein gel (Supplementary Fig. 4)".

() Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018

¹Infectious Diseases, Novartis Institutes for Biomedical Research, Emeryville, CA, USA. ²Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA. ³Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland. Correspondence and requests for materials should be addressed to R.C. (email: rajiv.chopra@novartis.com) or T.U. (email: tsuyoshi.uehara@gmail.com)